Our previous work demonstrated that T-cell immune inhibitory receptors, such as program death-1 (PD-1), T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin mucin 3 (Tim-3), and T lymphocyte activation gene-3 (LAG-3), show increased expression in T cells from patients with newly diagnosed AML (AMLy-DN) and those with relapsed AML. This evidence concerns the gene LAG3 and acute myeloid leukemia.